Maves (Homera Health) vs Enhance MD
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Maves (Homera Health)
Best for $99 first-month semaglutide with men's-health and body-optimization framingStarting at $99/mo
Enhance MD
Best for lab-monitored compounded GLP-1 with mandatory video visitStarting at $49/mo
Side-by-Side Comparison
| Feature | Maves (Homera Health) | Enhance MD |
|---|---|---|
| Overall Score | 7.6/10 | ✓8.6/10 |
| Starting Price | $99/mo | ✓$49/mo |
| Editorial Rating | 3.8 ★ /5 | ✓4.3 ★ /5 |
| Features | ✓7 features | 6 features |
| States Available | ✓50 | 39 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Maves (Homera Health)
Pros
- ✓LegitScript Certified
- ✓Publishes the FDA compounded-medication disclaimer
- ✓$99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- ✓All 50 states covered, stated explicitly
- ✓Both brand (Maves) and parent (Homera Health) disclosed for accountability
- ✓All-inclusive pricing — consult, meds, clinical support, and free shipping with no hidden fees
Cons
- ✗503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- ✗Tirzepatide pricing not stated on the homepage — only listed as an offering
- ✗Named medical director / clinical leadership not disclosed
- ✗Refund and cancellation policy not detailed publicly
- ✗Corporate address and arbitration venue not disclosed
- ✗$99/mo is first-month only — refill/standard pricing not shown and may step up
Enhance MD
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Low first-month intro pricing: $49 Core, $99 Advanced, $189 Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro pricing resets to full tier rate after 30 days — the $49/$99/$189 figures aren't ongoing cost
Our Verdict
Enhance MD edges out Maves (Homera Health) with a higher overall score of 8.6/10 and is particularly strong for lab-monitored compounded GLP-1 with mandatory video visit. Maves (Homera Health) remains a solid alternative, especially if you're looking for $99 first-month semaglutide with men's-health and body-optimization framing.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Maves (Homera Health) and Enhance MD head-to-heads in the same category.
- Maves (Homera Health) vs CoreAge Rx
- Maves (Homera Health) vs TrimRx
- Maves (Homera Health) vs Amazon One Medical
- Enhance MD vs NovoCare Pharmacy
- Enhance MD vs Vytora Health
- Enhance MD vs Noom Med
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.